Company registration number 09921792 (England and Wales)
THAROS LIMITED
UNAUDITED FINANCIAL STATEMENTS
FOR THE YEAR ENDED 31 DECEMBER 2024
PAGES FOR FILING WITH REGISTRAR
THAROS LIMITED
CONTENTS
Page
Balance sheet
1 - 2
Statement of changes in equity
3
Notes to the financial statements
4 - 10
THAROS LIMITED
BALANCE SHEET
AS AT 31 DECEMBER 2024
31 December 2024
- 1 -
2024
2023
as restated
Notes
£
£
£
£
Fixed assets
Intangible assets
4
40,454
85,131
Investments
5
1,084
1,084
41,538
86,215
Current assets
Stocks
32,558
25,165
Debtors
6
162,821
110,397
Cash at bank and in hand
22,702
123,655
218,081
259,217
Creditors: amounts falling due within one year
7
(303,768)
(308,424)
Net current liabilities
(85,687)
(49,207)
Total assets less current liabilities
(44,149)
37,008
Creditors: amounts falling due after more than one year
8
(140,666)
(146,284)
Net liabilities
(184,815)
(109,276)
Capital and reserves
Called up share capital
9
4,461
4,413
Share premium account
2,276,326
2,210,868
Other reserves
872,184
801,116
Profit and loss reserves
(3,337,786)
(3,125,673)
Total equity
(184,815)
(109,276)
THAROS LIMITED
BALANCE SHEET (CONTINUED)
AS AT 31 DECEMBER 2024
31 December 2024
- 2 -

For the financial year ended 31 December 2024 the company was entitled to exemption from audit under section 477 of the Companies Act 2006 relating to small companies.

The members have not required the company to obtain an audit of its financial statements for the year in question in accordance with section 476.

The directors acknowledge their responsibilities for complying with the requirements of the Companies Act 2006 with respect to accounting records and the preparation of financial statements.

These financial statements have been prepared and delivered in accordance with the provisions applicable to companies subject to the small companies regime.

The directors of the company have elected not to include a copy of the profit and loss account within the financial statements.true

The financial statements were approved by the board of directors and authorised for issue on 23 September 2025 and are signed on its behalf by:
Lord D Dundonald
Director
Company registration number 09921792 (England and Wales)
THAROS LIMITED
STATEMENT OF CHANGES IN EQUITY
FOR THE YEAR ENDED 31 DECEMBER 2024
- 3 -
Share capital
Share premium account
Other Reserves
Profit and loss reserves
Total
Notes
£
£
£
£
£
As restated for the period ended 31 December 2023:
Balance at 1 January 2023
3,952
1,872,274
246,961
(2,570,915)
(447,728)
Year ended 31 December 2023:
Loss and total comprehensive income
-
-
-
(556,347)
(556,347)
Issue of share capital
9
461
338,594
-
-
339,055
Share warrants issued
10
-
-
555,744
-
0
555,744
Lapse of share options
-
-
(1,589)
1,589
-
Balance at 31 December 2023
4,413
2,210,868
801,116
(3,125,673)
(109,276)
Year ended 31 December 2024:
Loss and total comprehensive income
-
-
-
(212,113)
(212,113)
Issue of share capital
9
48
65,458
-
-
65,506
Share warrants issued
10
-
-
71,068
-
0
71,068
Balance at 31 December 2024
4,461
2,276,326
872,184
(3,337,786)
(184,815)
THAROS LIMITED
NOTES TO THE FINANCIAL STATEMENTS
FOR THE YEAR ENDED 31 DECEMBER 2024
- 4 -
1
Accounting policies
Company information

Tharos Limited is a private company limited by shares incorporated in England and Wales. The registered office is 34 High Street, Aldridge, Walsall, West Midlands, WS9 8LZ.

1.1
Accounting convention

These financial statements have been prepared in accordance with FRS 102 “The Financial Reporting Standard applicable in the UK and Republic of Ireland” (“FRS 102”) and the requirements of the Companies Act 2006 as applicable to companies subject to the small companies regime. The disclosure requirements of section 1A of FRS 102 have been applied other than where additional disclosure is required to show a true and fair view.

The financial statements are prepared in sterling, which is the functional currency of the company. Monetary amounts in these financial statements are rounded to the nearest £.

The financial statements have been prepared under the historical cost convention. The principal accounting policies adopted are set out below.

1.2
Prior period error

During the year, it was identified that some warrants issued in 2023 were not recorded. The change has resulted in losses at 31 December 2023 increasing by £435,685.

1.3
Going concern

These financial statements are prepared on the going concern basis. The directors have a reasonable expectation that the company will continue in operational existence for the foreseeable future.true

 

In assessing the going concern basis, the directors have considered the company’s business activities and the financial position of the company. As at 31 December 2024 the company had cash reserves of £22,702 had a net current liabilities position of £85,687, and net liabilities position of £184,815. During the year to 31 December 2024 the company incurred a loss after taxation of £212,113.

 

The directors are actively pursuing, and are progressed in obtaining, substantial additional equity funding that will see the entity secure sufficient resources to continue to operate and meet its obligations for the foreseeable future. In addition, at the date the financial statements are approved, the directors have agreed with loan note holders an extension of the Secured Loan Note until December 2025.  As such the directors have adopted the going concern basis in the preparation of the financial statements.

 

There is a risk that equity funding may not be secured within the expected timeframes, in which case the directors would look to procure sufficient alternative funding to bridge the gap, noting that business is close to operational breakeven at the date the financial statements are approved.

1.4
Turnover

Turnover is recognised at the fair value of the consideration received or receivable for goods and services provided in the normal course of business, and is shown net of VAT and other sales related taxes. The fair value of consideration takes into account trade discounts, settlement discounts and volume rebates.

1.5
Research and development expenditure

Research expenditure is written off against profits in the year in which it is incurred. Identifiable development expenditure is capitalised to the extent that the technical, commercial and financial feasibility can be demonstrated. In this situation, the expenditure is deferred and amortised over the period during which the company is expected to benefit.

THAROS LIMITED
NOTES TO THE FINANCIAL STATEMENTS (CONTINUED)
FOR THE YEAR ENDED 31 DECEMBER 2024
1
Accounting policies
(Continued)
- 5 -
1.6
Intangible fixed assets other than goodwill

Intangible assets acquired separately from a business are recognised at cost and are subsequently measured at cost less accumulated amortisation and accumulated impairment losses.

Amortisation is recognised so as to write off the cost or valuation of assets less their residual values over their useful lives on the following bases:

Development costs
20% straight line
1.7
Fixed asset investments

Interests in subsidiaries and associates are initially measured at cost and subsequently measured at cost less any accumulated impairment losses. The investments are assessed for impairment at each reporting date and any impairment losses or reversals of impairment losses are recognised immediately in profit or loss.

A subsidiary is an entity controlled by the company. Control is the power to govern the financial and operating policies of the entity so as to obtain benefits from its activities.

An associate is an entity, being neither a subsidiary nor a joint venture, in which the company holds a long-term interest and where the company has significant influence. The company considers that it has significant influence where it has the power to participate in the financial and operating decisions of the associate.

1.8
Impairment of fixed assets

At each reporting period end date, the company reviews the carrying amounts of its tangible and intangible assets to determine whether there is any indication that those assets have suffered an impairment loss. If any such indication exists, the recoverable amount of the asset is estimated in order to determine the extent of the impairment loss (if any). Where it is not possible to estimate the recoverable amount of an individual asset, the company estimates the recoverable amount of the cash-generating unit to which the asset belongs.

1.9
Stocks

Stocks are stated at the lower of cost and estimated selling price less costs to complete and sell. Cost comprises direct materials and, where applicable, direct labour costs and those overheads that have been incurred in bringing the stocks to their present location and condition.

At each reporting date, an assessment is made for impairment. Any excess of the carrying amount of stocks over its estimated selling price less costs to complete and sell is recognised as an impairment loss in profit or loss. Reversals of impairment losses are also recognised in profit or loss.

1.10
Cash at bank and in hand

Cash and cash equivalents are basic financial assets and include cash at bank only.

1.11
Financial instruments

The company has elected to apply the provisions of Section 11 ‘Basic Financial Instruments’ and Section 12 ‘Other Financial Instruments Issues’ of FRS 102 to all of its financial instruments.

 

Financial instruments are recognised in the company's balance sheet when the company becomes party to the contractual provisions of the instrument.

 

Financial assets and liabilities are offset, with the net amounts presented in the financial statements, when there is a legally enforceable right to set off the recognised amounts and there is an intention to settle on a net basis or to realise the asset and settle the liability simultaneously.

THAROS LIMITED
NOTES TO THE FINANCIAL STATEMENTS (CONTINUED)
FOR THE YEAR ENDED 31 DECEMBER 2024
1
Accounting policies
(Continued)
- 6 -
Basic financial assets

Basic financial assets, which include trade debtors, amounts owed by group undertakings and undertakings in which the company has a participating interest, other debtors and cash and bank balances, are initially measured at transaction price including transaction costs and are subsequently carried at amortised cost using the effective interest method unless the arrangement constitutes a financing transaction, where the transaction is measured at the present value of the future receipts discounted at a market rate of interest. Financial assets classified as receivable within one year are not amortised.

Classification of financial liabilities

Financial liabilities and equity instruments are classified according to the substance of the contractual arrangements entered into. An equity instrument is any contract that evidences a residual interest in the assets of the company after deducting all of its liabilities.

Basic financial liabilities

Basic financial liabilities, including trade creditors, taxation and social security and other creditors are initially recognised at transaction price unless the arrangement constitutes a financing transaction, where the debt instrument is measured at the present value of the future payments discounted at a market rate of interest. Financial liabilities classified as payable within one year are not amortised.

 

Debt instruments are subsequently carried at amortised cost, using the effective interest rate method.

 

Trade creditors are obligations to pay for goods or services that have been acquired in the ordinary course of business from suppliers. Amounts payable are classified as current liabilities if payment is due within one year or less. If not, they are presented as non-current liabilities. Trade creditors are recognised initially at transaction price and subsequently measured at amortised cost using the effective interest method.

1.12
Equity instruments

Equity instruments issued by the company are recorded at the proceeds received, net of transaction costs.

 

1.13
Taxation

The tax expense represents the sum of the tax currently payable and deferred tax.

Current tax

The tax currently payable is based on taxable profit for the year. Taxable profit differs from net profit as reported in the profit and loss account because it excludes items of income or expense that are taxable or deductible in other years and it further excludes items that are never taxable or deductible. The company’s liability for current tax is calculated using tax rates that have been enacted or substantively enacted by the reporting end date.

Deferred tax

Deferred tax liabilities are generally recognised for all timing differences and deferred tax assets are recognised to the extent that it is probable that they will be recovered against the reversal of deferred tax liabilities or other future taxable profits. Such assets and liabilities are not recognised if the timing difference arises from goodwill or from the initial recognition of other assets and liabilities in a transaction that affects neither the tax profit nor the accounting profit.

 

The carrying amount of deferred tax assets is reviewed at each reporting end date and reduced to the extent that it is no longer probable that sufficient taxable profits will be available to allow all or part of the asset to be recovered. Deferred tax is calculated at the tax rates that are expected to apply in the period when the liability is settled or the asset is realised. Deferred tax is charged or credited in the profit and loss account, except when it relates to items charged or credited directly to equity, in which case the deferred tax is also dealt with in equity. Deferred tax assets and liabilities are offset when the company has a legally enforceable right to offset current tax assets and liabilities and the deferred tax assets and liabilities relate to taxes levied by the same tax authority.

THAROS LIMITED
NOTES TO THE FINANCIAL STATEMENTS (CONTINUED)
FOR THE YEAR ENDED 31 DECEMBER 2024
1
Accounting policies
(Continued)
- 7 -
1.14
Retirement benefits

Payments to defined contribution retirement benefit schemes are charged as an expense as they fall due.

1.15
Share-based payments

Equity-settled share-based payments are measured at fair value at the date of grant by reference to the fair value of the equity instruments granted using the Black-Scholes model. The fair value determined at the grant date is expensed on a straight-line basis over the vesting period, based on the estimate of shares that will eventually vest. A corresponding adjustment is made to equity.

1.16
Foreign exchange

Transactions in currencies other than pounds sterling are recorded at the rates of exchange prevailing at the dates of the transactions. At each reporting end date, monetary assets and liabilities that are denominated in foreign currencies are retranslated at the rates prevailing on the reporting end date. Gains and losses arising on translation in the period are included in profit or loss.

2
Judgements and key sources of estimation uncertainty

In the application of the company’s accounting policies, the directors are required to make judgements, estimates and assumptions about the carrying amount of assets and liabilities that are not readily apparent from other sources. The estimates and associated assumptions are based on historical experience and other factors that are considered to be relevant. Actual results may differ from these estimates.

 

The estimates and underlying assumptions are reviewed on an ongoing basis. Revisions to accounting estimates are recognised in the period in which the estimate is revised where the revision affects only that period, or in the period of the revision and future periods where the revision affects both current and future periods.

3
Employees

The average monthly number of persons (including directors) employed by the company during the year was:

2024
2023
Number
Number
Total
6
4
THAROS LIMITED
NOTES TO THE FINANCIAL STATEMENTS (CONTINUED)
FOR THE YEAR ENDED 31 DECEMBER 2024
- 8 -
4
Intangible fixed assets
Development costs
£
Cost
At 1 January 2024 and 31 December 2024
931,121
Amortisation and impairment
At 1 January 2024
845,990
Amortisation charged for the year
44,677
At 31 December 2024
890,667
Carrying amount
At 31 December 2024
40,454
At 31 December 2023
85,131
5
Fixed asset investments
2024
2023
£
£
Shares in group undertakings and participating interests
1,084
1,084
6
Debtors
2024
2023
Amounts falling due within one year:
£
£
Trade debtors
3,951
7,599
Amounts owed by group undertakings and undertakings in which the company has a participating interest
150,157
99,932
Other debtors
8,713
2,866
162,821
110,397
7
Creditors: amounts falling due within one year
2024
2023
£
£
Trade creditors
81,315
107,829
Taxation and social security
3,277
15,163
Other creditors
219,176
185,432
303,768
308,424

Included within other creditors due within one year as at 31 December 2024 is a loan of £10,056 (2023 - £10,027) secured by fixed and floating charges over the company's assets.

 

THAROS LIMITED
NOTES TO THE FINANCIAL STATEMENTS (CONTINUED)
FOR THE YEAR ENDED 31 DECEMBER 2024
- 9 -
8
Creditors: amounts falling due after more than one year
2024
2023
£
£
Other creditors
140,666
146,284

Included within other creditors due after one year as at 31 December 2024 is a loan of £138,254 (2023 - £138,284) secured by fixed and floating charges over the company's assets.

 

9
Called up share capital
2024
2023
2024
2023
Ordinary share capital
Number
Number
£
£
Issued and fully paid
Ordinary shares of 0.1p each
4,461,310
4,412,865
4,461
4,413

During the year, 48,440 Ordinary shares of 0.1p each were issued for a total consideration of £65,506.

 

10
Share-based payment transactions
Number of share options/warrants
Weighted average exercise price
2024
2023
2024
2023
Number
Number
£
£
Outstanding at 1 January 2024
737,534
278,953
0.01
0.02
Granted
48,396
461,477
0.01
0.01
Expired
-
0
(2,896)
0
-
0
1.25
Outstanding at 31 December 2024
785,930
737,534
0.01
0.01
Exercisable at 31 December 2024
785,930
737,534
0.01
0.01

The options outstanding at 31 December 2024 had an exercise price of between £0.0001 and £1.50, and a contractual life of between 5 and 10 years.

Inputs were as follows:
2024
2023
Weighted average share price
0.47
0.98
Weighted average exercise price
0.01
0.01
Expected volatility
50.00
50.00
Expected life
10.00
10.00
Risk free rate
0.66
1.40
THAROS LIMITED
NOTES TO THE FINANCIAL STATEMENTS (CONTINUED)
FOR THE YEAR ENDED 31 DECEMBER 2024
10
Share-based payment transactions
(Continued)
- 10 -

During the year, the company recognised expenses of £71,068 (2023:£555,744), which related to equity share based payment transactions.

 

11
Financial commitments, guarantees and contingent liabilities

Included within other creditors is a balance of £73,631 (2023 £73,631) due to a company controlled by an ex-director. This balance may be disputed and if so, it is highly likely that the company will incur interest charges.

 

12
Related party transactions

Any directors or senior employees who have authority and responsibility for controlling the activities of the company are considered to be key management personnel. Total remuneration in respect of these individuals is £72,773 (2023: £143,812).

 

At 31 December 2023 included within debtors is an amount of £150,157 (2023: £99,932) due from related parties and within creditors is an amount of £1,099 (2021: £175,217) due to related parties.

 

13
Prior period adjustment
Reconciliation of changes in equity
The prior period adjustments do not give rise to any effect upon equity.
2023
Analysis of the effect upon equity
Other reserves
435,685
Profit and loss reserves
(435,685)
-
Reconciliation of changes in loss for the previous financial period
2023
£
Adjustments to prior year
Warrants issued in 2023
(435,685)
Loss as previously reported
(120,662)
Loss as adjusted
(556,347)
Notes to reconciliation

During the year, it was identified that some warrants issued in 2023 were not recorded. The change has resulted in losses at 31 December 2023 increasing by £435,685.

2024-12-312024-01-01falsefalsefalse23 September 2025CCH SoftwareCCH Accounts Production 2025.200No description of principal activityLord D DundonaldDr R WaringProfessor T Forcht-DagiMr W R F Addison099217922024-01-012024-12-31099217922024-12-31099217922023-12-3109921792core:DevelopmentCostsCapitalisedDevelopmentExpenditure2024-12-3109921792core:DevelopmentCostsCapitalisedDevelopmentExpenditure2023-12-3109921792core:CurrentFinancialInstrumentscore:WithinOneYear2024-12-3109921792core:CurrentFinancialInstrumentscore:WithinOneYear2023-12-3109921792core:ShareCapital2024-12-3109921792core:ShareCapital2023-12-3109921792core:SharePremium2024-12-3109921792core:SharePremium2023-12-3109921792core:OtherMiscellaneousReserve2024-12-3109921792core:OtherMiscellaneousReserve2023-12-3109921792core:RetainedEarningsAccumulatedLosses2024-12-3109921792core:RetainedEarningsAccumulatedLosses2023-12-3109921792core:ShareCapital2022-12-3109921792core:SharePremium2022-12-3109921792core:RetainedEarningsAccumulatedLosses2022-12-3109921792core:ShareCapitalOrdinaryShareClass12024-12-3109921792core:ShareCapitalOrdinaryShareClass12023-12-3109921792bus:Director12024-01-012024-12-3109921792core:RetainedEarningsAccumulatedLosses2023-01-012023-12-31099217922023-01-012023-12-3109921792core:RetainedEarningsAccumulatedLosses2024-01-012024-12-3109921792core:ShareCapital2023-01-012023-12-3109921792core:SharePremium2023-01-012023-12-3109921792core:ShareCapital2024-01-012024-12-3109921792core:SharePremium2024-01-012024-12-3109921792core:IntangibleAssetsOtherThanGoodwill2024-01-012024-12-3109921792core:DevelopmentCostsCapitalisedDevelopmentExpenditure2023-12-3109921792core:DevelopmentCostsCapitalisedDevelopmentExpenditure2024-01-012024-12-3109921792core:CurrentFinancialInstruments2024-12-3109921792core:CurrentFinancialInstruments2023-12-3109921792core:WithinOneYear2024-12-3109921792core:WithinOneYear2023-12-3109921792core:Non-currentFinancialInstruments2024-12-3109921792core:Non-currentFinancialInstruments2023-12-3109921792bus:OrdinaryShareClass12024-01-012024-12-3109921792bus:OrdinaryShareClass12024-12-3109921792bus:OrdinaryShareClass12023-12-31099217922023-12-31099217922022-12-3109921792bus:PrivateLimitedCompanyLtd2024-01-012024-12-3109921792bus:FRS1022024-01-012024-12-3109921792bus:AuditExemptWithAccountantsReport2024-01-012024-12-3109921792bus:Director22024-01-012024-12-3109921792bus:Director32024-01-012024-12-3109921792bus:Director42024-01-012024-12-3109921792bus:SmallCompaniesRegimeForAccounts2024-01-012024-12-3109921792bus:FullAccounts2024-01-012024-12-31xbrli:purexbrli:sharesiso4217:GBP